Indeed, in BRCA1- or ATM-mutated breast, ovarian and lung cancer lines, low EME1 levels associated with decreased Olaparib sensitivity (Fig. 6i), which was not the case in BRCA2-mutated or unaltered cells. Here, EME1 is linked to lung carcinoma.